Lincocin Aquadrops 50 mg/ml (20 ml)

Lincocin (lincomycin hydrochloride) is indicated in the treatment of infections caused by Gram-positive organisms that are sensitive to its action, particularly streptococci and staphylococci.

Key Benefits

• Proven effective in treating the most common upper respiratory tract infections, septicemia, and infections of the skin and adjoining tissues.
• Treats staphylococcal infections resistant to other antibiotics and sensitive to lincomycin.
• Rapidly absorbed following either oral or parenteral administration.
• Injectable is easy to use, with no stinging following administration.
• No refrigeration needed.

Dogs: Lincocin is indicated for the treatment of skin infections (pustular dermatitis, abscesses, infected wounds [including bite and fight wounds]), upper respiratory tract infections (tonsillitis, laryngitis), metritis, and secondary bacterial infections associated with the canine distemper-hepatitis complex.

Cats: Lincocin is indicated for the treatment of localized infections, such as abscesses, pneumonitis, and feline rhinotracheitis.

Indications & Usage

LINCOCIN products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. The drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues.

Systemic therapy with LINCOCIN has been shown to be of benefit in many animals with pustular dermatitis. As with all antibiotics, in vitro sensitivity studies should be performed before LINCOCIN is utilized as sole antibiotic therapy.

LINCOCIN has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. The drug may be administered in combination therapy with other antimicrobial agents when indicated.

No serious hypersensitivity reactions have been reported and many animals have received LINCOCIN repeatedly without developing evidence of hypersensitivity.

In dogs, LINCOCIN has demonstrated excellent efficacy in the treatment of upper respiratory infections and of skin diseases, particularly those caused by staphylococcus and streptococcus organisms. LINCOCIN has demonstrated efficacy even in some chronic conditions of long standing and in infections which have resisted treatment with other antibacterial agents.

Infections successfully treated with LINCOCIN include pustular dermatitis, abscesses, infected wounds (including bite and fight wounds), tonsillitis, laryngitis, metritis, and secondary bacterial infections associated with the canine distemper-hepatitis complex.

In cats, LINCOCIN has demonstrated efficacy in the treatment of localized infections, such as abscesses following fight wounds, pneumonitis, and feline rhinotracheitis.

Success in the treatment of viral diseases must be attributed to the control of susceptible secondary bacterial invaders rather than to any effect of LINCOCIN on the virus.

Oral: 10 mg per pound of body weight every 12 hours or 7 mg per pound every 8 hours.

Intramuscular: 10 mg per pound of body weight once a day or 5 mg per pound every 12 hours.

Intravenous: 5 to 10 mg per pound of body weight one or two times per day diluted with 5 percent glucose in water or normal saline and given as a drip infusion.

Treatment with Lincocin products may be continued for periods as long as 12 days if clinical judgment indicates.

As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe.

Caution:

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Animal Safety:

The acute LD50 intraperitoneally in mice is 1000 mg/kg and orally in rats is 15,645 mg/kg. Lincocin was well tolerated orally in rats and dogs at doses up to 300 mg/kg/day for periods up to one year. Parenteral dosages of up to 60 mg/kg/day for 30 days subcutaneously in the rat and intramuscularly in the dog produced no significant systemic effects or pathological findings at necropsy.

Lincocin at a daily dose level of 75 mg/kg subcutaneously was injected into mature male and female rats during a prebreeding period of 60 days and throughout two mating cycles (84 days). No evidence was obtained that Lincocin exerted any effects on breeding performance and no drug-induced anomalies were discovered in the young. Similarly no evidence was obtained that Lincocin, when given in sustained parenteral dosage of 50 mg/kg daily to pregnant bitches, produced a teratogenic effect on the canine embryo.

The subcutaneous LD50 value in the newborn rat was determined to be 783 mg/kg. Newborn rats and canine pups have tolerated multiple doses of 30-90 mg/kg/day of the drug without evidence of ill effects.

Adverse Reactions:

Loose stools occasionally have been observed in dogs and cats on oral doses. Vomiting in cats has occasionally been reported following oral administration.

Intramuscularly and intravenously, Lincocin products have demonstrated excellent local tolerance with no reports of pain or inflammation following injection.

Precautions:

The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms-particularly yeasts. Should superinfections occur, appropriate measures should be taken.

Warning:

Not for human use.

Contraindications:

As with all drugs, the use of Lincocin products is contraindicated in animals previously found to be hypersensitive to the drug.

Lincocin should not be given to animals with known preexisting monilial infections.

The following species are sensitive to the gastrointestinal effects of lincomycin: rabbits, hamsters, guinea pigs and horses. Therefore, the administration of Lincocin should be avoided in these species.